New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For VAL;AVP;KORS;BYD;ZIOP;FOSL;QCOM;LVLT;BCS;NTWK;FB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
January 21, 2015
09:44 EDTQCOMQualcomm slips on reports its chips won't be used in new Galaxy phone
Subscribe for More Information
09:37 EDTQCOMQualcomm shares defended at Credit Suisse
Subscribe for More Information
09:25 EDTKORSMichael Kors estimates remain ahead of consensus at ITG Research
ITG Research's data indicates Michael Kors year-over-year traffic trends ramped in October and peaked in early December but remains substantially stronger than trends observed coming out of Q2 and the firm's Q3 revenue estimates remains above consensus.
08:13 EDTQCOMQualcomm slides after reportedly being dropped from Galaxy phone
Samsung Electronics (SSNLF), which is trying to become more self-sufficient and give a boost to its own processor-making unit, will reportedly drop Qualcomm’s (QCOM) Snapdragon chip in favor of its own microprocessors in the next Galaxy S smartphone, according to a report from Bloomberg that cited people with direct knowledge of the matter. Shares of Qualcomm are down 2.7% to $70.50 in pre-market trading following the Bloomberg report.
08:00 EDTKORSMichael Kors upgraded to Outperform at Cowen
Subscribe for More Information
06:02 EDTKORSMichael Kors upgraded to Outperform from Market Perform at Cowen
05:53 EDTQCOMStocks with implied volatility movement; IBM QCOM
Stocks with implied volatility movement; IBM (IBM) 27, Qualcomm (QCOM) 33 according to iVolatility.
05:53 EDTQCOMSamsung drops Qualcomm chip from next Galaxy smartphone, Bloomberg reports
Subscribe for More Information
05:30 EDTLVLTLevel 3 upgraded to Outperform from Market Perform at Wells Fargo
Subscribe for More Information
January 20, 2015
13:21 EDTZIOPCAR T-Cell therapy drug stocks down sharply following NY Times story
Shares of biotechnology companies that are developing chimeric antigen receptor T cells or CAR T therapy drugs are falling sharply after a New York Times story titled "Riding High, Biotech Firms Remain Wary." WHAT'S NEW: Over the weekend, the New York Times published the story that struck a cautionary tone on the CAR-T therapy drugs. In this form of cancer treatment the patients own immune system cells are genetically manipulated to battle tumors. The New York Times story noted that there were some notable outcomes in the treatment of leukemia and lymphoma with the CAR T treatments but highlighted that the "technique is still early in development and can cause severe side effects." WHAT'S NOTABLE. Early last week, Intrexon (XON) and its oncology partner, ZIOPHARM Oncology (ZIOP), announced an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sub-licensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. Both companies' shares were up sharply following the announcement ZIOPHARM was up around 55% and Intrexon up over 30% the day following the announcement. PRICE ACTION: Shares of drug companies in the space are sharply lower in midday trading, with ZIOPHARM Oncology and Kite Pharma (KITE) each down over 9%, Intrexon down almost 12%, and Bellicum Pharmaceutical (BLCM) and bluebird bio (BLUE) each down almost 5%. Reference Link
07:30 EDTBCSU.K. banks see Bitcoin as threat to sterling, boon to terrorists, Telegraph says
Subscribe for More Information
07:28 EDTBCSTreasury Institute for Higher Education to hold a symposium
Subscribe for More Information
06:57 EDTFBFacebook to upgrade Messenger app, experiment with revenue generation, WSJ says
Subscribe for More Information
06:57 EDTFOSL, KORSMichael Kors relative valuation looks compelling, says Piper Jaffray
Subscribe for More Information
06:41 EDTFOSLFossil downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray downgraded Fossil to Neutral saying the company's North American growth could slow further while foreign currency is a headwind with a third of its sales coming from Europe. Piper lowered its price target for shares to $104 from $133.
06:09 EDTAVPAvon Products implied volatility of 76 at upper end of index mean range
Subscribe for More Information
06:02 EDTFBFacebook acquires boutique firm Teehan+Lax, terms not disclosed
Toronto-based boutique firm Teehan+Lax announced in a blog post on Friday that the company will join Facebook's design team in California. T+L said "In a few weeks we will be moving to the San Francisco Bay Area. This will mean saying goodbye to family, friends, Toronto, and Teehan+Lax." Terms of the deal have not been disclosed. Reference Link
05:54 EDTZIOPStocks with implied volatility movement; ZIOP INVN
Subscribe for More Information
January 18, 2015
16:34 EDTFBFacebook job listings hint at push into virtual reality, Reuters says
Subscribe for More Information
16:16 EDTBCSBarclays loses 'millions' on Swiss franc volatility, Reuters says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use